1003846-21-6

Basic information

• Product Name: 1-(2-Tetrahydropyranyl)-1H-pyrazole-4-boronic acid pinacol ester
• Synonyms: 1-(2-Tetrahydropyranyl)-1H-pyrazole-4-boronic acid pinacol ester;1-(Tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-(2-Tetrahydropyranyl)-1...;1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(SALTDATA: FREE);1-(Tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-boronic acid, pinacol ester;1-(oxan-2-yl)-4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-Tetrahydropyran-2-yl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyrazole;1-(tetrahydro-2H-pyran-2-yl)-4-(4
• CAS NO: 1003846-21-6
• Molecular Formula: C₁₄H₂₃BN₂O₃
• Molecular Weight: 296.1703
• Mol File: 1003846-21-6.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 413.793 °C at 760 mmHg
• Flash Point: 204.055 °C
• Appearance: /
• Density: 1.161 g/cm³
• Storage Temp.: Refrigerated.
• PKA: 1.95±0.19(Predicted)
• CAS DataBase Reference: 1-(2-Tetrahydropyranyl)-1H-pyrazole-4-boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Tetrahydropyranyl)-1H-pyrazole-4-boronic acid pinacol ester(1003846-21-6)
• EPA Substance Registry System: 1-(2-Tetrahydropyranyl)-1H-pyrazole-4-boronic acid pinacol ester(1003846-21-6)

Safety Data

• Hazardous Substances Data: 1003846-21-6(Hazardous Substances Data)

Usage

General Description

1-(2-Tetrahydropyranyl)-1H-pyrazole-4-boronic acid pinacol ester is a boronic acid derivative used in organic synthesis and medicinal chemistry. It contains a boronic acid functional group, which is a versatile building block for the synthesis of pharmaceuticals and other organic compounds. The pinacol ester moiety provides stability and solubility in organic solvents, making it a useful reagent for Suzuki-Miyaura cross-coupling reactions and other chemical transformations. 1-(2-Tetrahydropyranyl)-1H-pyrazole-4-boronic acid pinacol ester has potential applications in the development of new drugs and materials due to its ability to participate in diverse chemical reactions.

InChI:InChI=1S/C14H23BN2O3/c1-13(2)14(3,4)20-15(19-13)11-9-16-17(10-11)12-7-5-6-8-18-12/h9-10,12H,5-8H2,1-4H3

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 1040377-02-3 4-bromo-1-(tetrahydro-2H-pyran-4-yl)- 1H-pyrazole 
• 73183-34-3 bis(pinacol)diborane 
• 82099-98-7 4-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole 
• 938066-17-2 4-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole 
• 1195-66-0 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 1160064-97-0 (2R,4S)-4-((3,5-bis-trifluoromethyl-benzyl)-{5-[1-(tetrahydro-pyran-2-yl)-1H-pyrazol-4-yl]-pyrimidin-2-yl}-amino)-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester 
• 1620400-82-9 C₁₉H₂₆N₂O 

Relevant articles and documents

PROCESS FOR THE MANUFACTURE OF 1,4-DISUBSTITUTED PYRIDAZINE COMPOUNDS

The invention relates to a novel process, novel process step(s) and novel intermediate(s) useful for the preparation of 1,4-disubstituted pyridazine compounds, such as 5-(1 H-Pyrazol-4-yl)-2-(6- ((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol.

Discovery and Optimization of Glucose Uptake Inhibitors

Aerobic glycolysis, originally identified by Warburg as a hallmark of cancer, has recently been implicated in immune cell activation and growth. Glucose, the starting material for glycolysis, is transported through the cellular membrane by a family of glucose transporters (GLUTs). Therefore, targeting glucose transporters to regulate aerobic glycolysis is an attractive approach to identify potential therapeutic agents for cancers and autoimmune diseases. Herein, we describe the discovery and optimization of a class of potent, orally bioavailable inhibitors of glucose transporters, targeting both GLUT1 and GLUT3.

3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.